Navigation Links
Proove Biosciences has presented at the Pain Society of the Carolinas Annual Meeting
Date:12/11/2014

IRVINE, CA (PRWEB) December 10, 2014

Proove Biosciences, a commercial and research leader in Personalized Medicine, presented research conducted through their genetic testing for drug responses.

The Pain Society of the Carolinas Annual Meeting focuses on the rapidly expanding field of pain management.

Genetic factors are believed to account for 20-95% of observed variation in a patient’s response to prescription drugs. However, this is not typically explored before the commencement of a prescription regime, as the role of unique genes is poorly understood. Overdoses of opioids such as Oxycodone and Hydrocodone are the second leading cause of accidental death in the United States. The misuse and abuse of opioid medication is seen as a major part of the Public Health Crisis of Prescription Drug Abuse.

In this study, conducted with data from a population of 1580 pain patients using oxycodone only, it is suggested that ANKK1 and DBH may play an active role in the observed differences in the therapeutic response to the use of Oxycodone. Also suggested is that response to opioid medications may be more influenced by the genes of the mesolimbic neural circuitry than previously thought.

“This new information could help guide future prescription decisions to avoid misuse and abuse.", says Bilikis.

About Proove Biosciences

Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We envision a future where physicians will know how patients are likely to respond to medications before writing a prescription. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at http://www.prweb.com/releases/2014/12/prweb12385099.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
2. Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
3. Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
4. Proove Biosciences Announces Sponsorship of National Drug Take Back Day and HC DrugFree
5. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
6. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
7. Proove Biosciences Will Be Exhibiting at the National Workers Compensation Conference and Expo on November 20-22
8. Proove Biosciences CEO Brian Meshkin Wins 2013 Bridging the Gap Award by the Greater Baltimore Committee
9. Proove Biosciences Successfully Presents Data and Exhibits at the Eastern Pain Association’s Annual Meeting in New York, New York
10. Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting
11. Proove Biosciences Exhibits Industry Leading Data and Research at PAINWeek 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):